Milestone Pharmaceuticals Inc. Total Liabilities and Equity
Milestone Pharmaceuticals Inc. (MIST) had Total Liabilities and Equity of $181.63 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $181.63M.
- 2026-03-31: Liabilities and Equity $193.73M.
- 2025-12-31: Liabilities and Equity $113.56M.
- 2025-09-30: Liabilities and Equity $87.75M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $181.63M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $193.73M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $113.56M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $87.75M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $47.42M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $61.88M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $75.50M 10-K · filed 2026-03-20 |
| 2024-09-30 | $82.71M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $89.23M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $96.00M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $75.23M 10-K · filed 2025-03-13 |
| 2023-09-30 | $87.12M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $97.02M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $111.08M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $74.48M 10-K · filed 2024-03-21 |
| 2022-09-30 | $85.77M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $91.30M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $105.80M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $119.85M 10-K · filed 2023-03-29 |
| 2021-09-30 | $133.78M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $145.50M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $138.44M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $149.97M 10-K · filed 2022-03-24 |
| 2020-09-30 | $108.80M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $93.14M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $105.16M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $123.43M 10-K · filed 2021-03-29 |
| 2019-09-30 | $141.89M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $151.84M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $77.59M 10-Q · filed 2019-06-19 |
| 2018-12-31 | $88.08M 10-K/A · filed 2020-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |